ClinicalTrials.gg
Enrolling by invitationNCT03976622INFLAMMAVitUpdated Jun 18, 2026

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

An observational study in Vitiligo, Psoriasis and Alopecia Areata, sponsored by University Hospital, Bordeaux. Enrolling by invitation at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University Hospital, Bordeaux · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years to 75 Years
Sex
All
01

Study summary

It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders

Read the detailed description

This study was a single-center prospective study to collect blood and skin tissue at the time of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or alopecia areata, in order to better understand and compare blood and skin immune response in chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and vitiligo.

02

Conditions studied

  • Vitiligo
  • Psoriasis
  • Alopecia Areata
  • Atopic Dermatitis

Keywords

  • Skin inflammation
  • Cytokines
03

In context

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

This study's planned enrollment of 450 is above the median of 114 across 67 observational studies indexed under Vitiligo.

Browse Vitiligo studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 806 studies on the registry; 197 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

450 patients (300 patients with vitiligo, 50 psoriasis patients, 50 patients with atopic dermatitis, 50 patients with alopecia areata)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 75 years;
  • Patients with non-segmental vitiligo;
  • Patients with plaque psoriasis;
  • Patients with atopic dermatitis;
  • Patients with alopecia areata sclerosis;
  • written consent, free, informed and signed by the patient and the investigator (before any examination required by the study);
  • Subject affiliated or beneficiary of a social security system.

Exclusion criteria

Exclusion Criteria:

  • Patients with segmental vitiligo
  • Patients under local treatment (topical -Calcineurin inhibitor) for less than two weeks.
  • Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks.
  • Pregnant or breastfeeding women
  • Patient (e) under guardianship
  • Patient (e) Non-affiliated (e) a social protection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • vitiligo

    Patients aged 18 to 75 years with non-segmental vitiligo;

    Biological: Blood samples · Biological: Skin biopsies

  • psoriasis

    Patients aged 18 to 75 years with plaque psoriasis;

    Biological: Blood samples · Biological: Skin biopsies

  • atopic dermatitis

    Patients aged 18 to 75 years with atopic dermatitis;

    Biological: Blood samples · Biological: Skin biopsies

  • alopecia areata

    Patients aged 18 to 75 years with alopecia areata sclerosis;

    Biological: Blood samples · Biological: Skin biopsies

Interventions

  • BiologicalBlood samples

    Blood samples: serum and PBMC

    Also known as: Blood samples: serum and PBMC

  • BiologicalSkin biopsies

    These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.

06

What researchers measure

Primary outcomes

  1. Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata

    Description of the phenotypic analysis of cutaneous T-cell and blood of vitiligo patients evaluated by flow cytometry

    Time frame: Day 1

07

Study locations

1 site
  • Service de Dermatologie - Hôpital Saint-André
    Bordeaux, Bordeaux 33075, France
08

References and documents

Publications

  • Jacquemin C, Taieb A, Boniface K, Seneschal J; FHU ACRONIM. Imbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo. Pigment Cell Melanoma Res. 2019 Jul;32(4):588-592. doi: 10.1111/pcmr.12763. Epub 2019 Feb 15. PubMed 30552832 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03976622
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jan 14, 2020
Primary completion
Jun 3, 2027 (estimated)
Completion
Jun 3, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Julien SENESCHAL, MD, PhD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion